- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01268202
Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis (PRAVACUR)
Molecular mechanisms involved in radio-induced fibrosis are assessed in UPRES EA 27-10 since 10 years. Besides the canonical TGFbeta/ Smad pathway involved in radio-induced fibrosis (RIF), the Rho/ROCK/CTGF cascade has been shown to be also implicated in molecular mechanisms of RIF. Curative administration of Pravastatin or ROCK specific inhibitors inhibits the chronically activated Rho/ROCK/CTGF pathway in vitro in human cells lines and ex vivo in human samples. In addition, the curative administration of Pravastatin improves established RIF in vivo. The investigators data suggest that the pravastatin-based strategy is an efficient and safe antifibrotic therapy, easily transferable into the clinic to improve the quality of life of long-term cancer survivors without interfering with prior anticancer treatment.
This clinical trial evaluates the curative efficacy of Pravastatine in patients who presented a cutaneous and/ or subcutaneous fibrosis (grade >= 2 according to NCI-CTCAE v4 toxicities scale) and who were treated by radiotherapy for a head and neck cancer. Patients will be treated by Pravastatin during 12 months. An intermediate evaluation of efficacy by ultrasound will be assessed at 6 months and at last, at the end of the treatment. Patients assessment will be performed at 6 and 12 months after the end of the treatment to look at a potential rebound effect.
Objective(s) of the clinical study
Main objective: To assess Pravastatin efficacy in established cutaneous and subcutaneous radio-induced fibrosis revealed from 6 to 24 months after head and neck radiotherapy.
Second objective: To evaluate radio-induced fibrosis regression during the year following treatment stop.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34298
- Centre Val D'Aurelle
-
Paris, France, 75015
- Hôpital Européen Georges Pompidou
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Grade >= 2 cutaneous and/or subcutaneous fibrosis (NCI-CTCAE v4 toxicities scale) revealed from 6 to 24 months after head and neck radiotherapy.
- Head and neck cancers treated by radiation therapy +/- chemotherapy, +/- surgery, with no evidence of progressive disease.
- Age >= 18
- Karnofsky PS ≥ 70
- normal renal function (plasmatic creatinine <= 130 micromol/l), normal cholesterol, normal hepatic function (total bilirubin <= 1.5 UNL, SGOT and SGPT <= 2 UNL)
- Written informed consent of the patient.
Exclusion Criteria:
- any chronic treatment by corticoids
- severe cardiac pathology
- patients already treated by statins or treated by fibrates, cyclosporine
- history of muscular toxicities when treated by fibrates or by statins
- Personal or familial history of hereditary muscular pathology
- Plasmatic CPK >3 UNL
- patient already included in another therapeutic trial with an experimental drug,
- pregnant patient or susceptible to pregnancy or breast feeding (patients in age to give birth must be placed under efficient contraception),
- a social or psychological condition that does not allow a positive patient's participation in the treatment and necessary medical follow-up to be envisaged,
- the patient is under legal restrained or tutelage.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pravastatin
Pravastatin : 40mg/day during 12 months
|
Pravastatin 40mg/day during 12 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
regression of radio-induced fibrosis (RIF) evaluated by high frequency ultrasound
Time Frame: 12 months
|
a decrease of the maximal thickness more than 30% compared to RIF before treatment.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fibrosis grade according to NCI-CTCAE v4 toxicities scale.
Time Frame: 12 months
|
12 months
|
|
Quality of life
Time Frame: 12 months
|
VQ-Dermato scale
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Sofia Rivera, MD, Gustave Roussy, Cancer Campus, Grand Paris
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSET 1383 - PRAVACUR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrosis
-
San Gerardo HospitalCompletedIdiopathic Pulmonary Fibrosis | Cardiac Fibrosis | Arterial FibrosisItaly
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Assistance Publique - Hôpitaux de ParisRecruitingIdiopathic Retroperitoneal FibrosisFrance
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
University of ParmaUnknownIdiopathic Retroperitoneal Fibrosis | Perianeurysmal Retroperitoneal Fibrosis | Chronic PeriaortitisItaly
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University Hospital, GrenobleNot yet recruiting
Clinical Trials on Pravastatin
-
Akros Pharma Inc.CompletedType II HyperlipidemiaNetherlands
-
Daiichi Sankyo, Inc.CompletedHypercholesterolemiaUnited States
-
National Center for Research Resources (NCRR)UnknownHeart DiseasesUnited States
-
Yonsei UniversityCompleted
-
Pontificia Universidad Catolica de ChileBristol-Myers SquibbWithdrawn
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPolycystic Kidney, Autosomal DominantUnited States
-
Arkansas Children's Hospital Research InstituteTerminatedEnd Stage Renal DiseaseUnited States
-
Mitsukoshi Health and Welfare FoundationDaiichi Sankyo Co., Ltd.; Ministry of Health, Labour and Welfare, JapanCompleted
-
Gachon University Gil Medical CenterCompleted
-
Bristol-Myers SquibbCompletedActue Coronary Syndromes